Bladder cancer targeted drug Erdafitinib Indian version

Erdafitinib (Erdafitinib) is a targeted drug for the treatment of bladder cancer. It is understood that there are currently no Indian versions of the original Erdafitinib drug or generic drugs on the market, but there may be Erdafitinib original drugs for sale in India. Erdafitinib is marketed to treat urothelial cancer (bladder cancer) that has spread or cannot be removed with surgery. It is used in patients whose cancer has an abnormal "FGFR" gene, and in patients who have tried at least one other platinum-containing chemotherapy drug without success.

Doctors test patients for the presence of the gene, and the drug is only available with a prescription. When deciding to use erdafitinib, patients must weigh the risks and benefits of taking this drug. The active ingredient in erdafitinib, an oral small molecule inhibitor of fibroblast growth factor (FGF) receptors 1 to 4, has been associated with high rates of serum enzyme elevations during treatment but not with clinically apparent cases of acute liver injury. Erdafitinib has also been associated with moderate elevations in serum aminotransferases, which are usually transient and not associated with symptoms or jaundice, and should warrant more careful follow-up monitoring if elevations are confirmed.

The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).